05:19 PM EDT, 06/05/2024 (MT Newswires) -- Halozyme Therapeutics ( HALO ) said Wednesday it obtained a European patent for its Enhanze drug delivery platform.

The new patent is subject to validation in 37 European countries and will expire on March 6, 2029, it said.

The company also said the patent prevents the reduction in the royalty rate on sales in Europe of Darzalex, which has received regulatory approvals as a subcutaneous product utilizing Enhanze technology.

The patent is not expected to have any impact on royalties under other Enhanze licenses with an issued or pending collaboration patent, it said.

Shares of the company rose more than 2% in after-hours activity.

Price: 46.69, Change: +1.04, Percent Change: +2.28